- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01671423
Use of a Single Dose of Oral Prednisone in the Treatment of Cellulitis
Study Overview
Detailed Description
This pilot study will be conducted in a prospective, double-blinded, placebo-controlled, randomized fashion using a convenience sample of 100 subjects who come to the ED with signs and symptoms of cellulitis. Initial medical assessment will be made by an attending/senior resident according with established clinical procedures, including the history, physical examination, and vital signs. If by clinical assessment the patients meet eligibility criteria, then they will be approached by a research associate for screening, informed consent process, enrollment in the study, and data collection.
After the subjects understand and sign the informed consent form, they will be randomized to either the placebo group or treatment group. The EMCP pharmacy will be in charge of the randomization process. Once randomized, a standard source document (see data management section and appendix C for details) will be filled with information given by the subjects and in their charts. While study medication is given (time zero), subjects will receive a Visual Analog Scale (VAS) to rate their pain upon initial presentation along with determination of size of the cellulitic area. This will be done by determining the longest axis of the cellulitic area and measuring it (in mm) from the most proximal/lateral end towards the most distal/medial end, excluding any lymphangitic spread. The most proximal and distal area of erythema will be outlined.
While the standard treatment of care for cellulitis will be circumscribed according to already established protocols, the class of antibiotics and pain control that patients receive will depend on their disposition:
If discharged:
- Antibiotic prescriptions will be TMP/SMX 160/800 mg (Bactrim DS), 2 pills PO BID and Cephalexin 500 mg PO qid; if allergic, Clindamycin 300 mg PO QID.
- Pain control: during stay in the ED subjects will receive, according to their allergic history and as long as the treating physician determines it is necessary to address the pain, two tablets of either Percocet 5/325 mg,Vicodin 5/500 mg (if allergic to Percocet), or Acetaminophen 500 mg as an only dose. Once discharged they will receive, according to their allergic history and the physician's clinical judgement, a prescription of 12 tablets of either Percocet 5/325 mg, Vicodin 5/500 mg (if allergic to Percocet), Tylenol #3 300/30 mg, or Acetaminophen 500 mg, one tablet PO q6 and PRN for pain. Pain medication must not include NSAIDs.
If admitted to observation unit: antibiotics will be IV Clindamycin 300 mg q6 hours; if allergic, IV Vancomycin 1 g q12 hours should be given. For pain control: Morphine 4 mg IV q4 hours and PRN pain; if allergic, Dilaudid 1 mg IV q4 hours and PRN if pain. Pain medication must not include NSAIDs. Once discharged, they will receive the same prescription as the discharged group of subjects.
In addition to the standard of care described and any additional medications deemed appropriate by the attending physician that do not represent a confounding factor to the study (NSAIDs, other antibiotics), subjects will also receive an additional pill which will be either prednisone 60 mg or placebo. If the treating physician feels it is in the best interest of the subject to break the protocol, the subject's participation in study procedures will end. Data that has already been collected will be kept, and may be analyzed separately. Once the subjects have received the study medications, they will follow their dispositions (either be discharged or be admitted in the observation's unit). To assure treatment compliance, the Research Associate will provide the subjects with antibiotics and pain medication treatment corresponding to the first 48 hours. After this landmark, the subjects will cover the rest of their treatment. Subjects will be instructed not to take any medication outside the prescription during the length of the study. If the subjects take NSAIDs during the first 48 hours, this could be considered a confounding factor. As such, subjects who take NSAIDs within the first 48 hours will have their participation in study procedures ended. Their already collected data will be kept and may be analyzed separately; however, if they take NSAIDs after the 48-hour visit their study participation will continue.
Subjects will be required to return to the ED after 48 hours and bring the remaining prescribed pain medications. They will meet a Research Associate for re-evaluation, which will be done by using a VAS, measuring the cellulitic area, and assessing the degree of usage of the prescribed pain medications. This second visit is not part of the standard of care so patients won't be required to receive a formal evaluation by an ED doctor nor register in triage. Financial compensation will be provided on completion of the 48 hour follow-up visit for all patients. A seventh (± one) day follow-up call will be done to assess pain severity, degree of symptomatic recovery and disappearance of the erythema, and need of additional medical assistance.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19141
- Albert Einstein Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 to 70 years
Current episode of cellulitis
- Erythema greater than 5 centimeters in any dimension
- Pain, swelling, warmth, and tenderness in the area without elevated borders
- Dispositioned for discharge from the Emergency Department or Observation
- Able to consent
Exclusion Criteria:
- Steroid use in the past 2 weeks
- History of adrenal insufficiency
- Any infection treated with antibiotics in the past 2 weeks
Allergy to:
- Steroids
- Acetaminophen
- Trimethoprim-Sulphamethoxazole (TMP/SMX), Cephalexin, and Clindamycin (must be allergic to all three for exclusion)
- Oxycodone and Hydrocodone (must be allergic to both for exclusion)
If subject is going to the Observation unit, allergy to:
- Clindamycin and Vancomycin (must be allergic to both for exclusion)
- Morphine and Hydromorphone (must be allergic to both for exclusion)
- Suspicion or presence of abscess
- Suspicion or presence of deep vein thrombosis
Suspicion or presence of severe sepsis, as defined by:
- Sepsis
- Hypotension (systolic pressure < 90 mmHg or reduction of 40 mmHg from baseline)
- Failure of single end organ
Suspicion or presence of septic shock, as defined by:
- Severe sepsis
- Hypotension that is refractory to fluid management
- Failure or more than one end organ
- Crepitus
- Change in mentation
- Tachycardia greater than 120 beats per minute
- Fever greater than or equal to 39 degrees Celsius
- Hospital admission
- Under 18 years of age, or over 70 years of age
- Pregnancy or breast feeding
- Police custody or prisoner
- Cognitive impairment
- Inability to consent
- Nursing home residents
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Prednisone
In addition to standard care for cellulitis, subject will receive a single 60 mg dose of Prednisone orally during their initial visit.
|
See "Prednisone" arm description
Other Names:
|
Placebo Comparator: Placebo
In addition to standard care for cellulitis, subjects will receive a single placebo pill to take during their initial visit.
|
See "Placebo" arm description
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Visual Analog Scale(VAS) for Pain - Day 1 to 48 Hours
Time Frame: Assessed once at day 1 and then once during the 48 hour follow-up
|
The level of pain as measured by a Visual Analog Scale(VAS) measured once at day 1 and once during the 48th hour follow-up visit.
Minimum value 0, maximum value 100mm, higher scores corresponds to more pain/worse outcomes.
|
Assessed once at day 1 and then once during the 48 hour follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Amount of Pain Medication - Day 1 to 48 Hours
Time Frame: Assessed once during the 48 hour follow-up
|
Number of times the subject needed to use pain medication between day 1 and the 48 hour follow-up
|
Assessed once during the 48 hour follow-up
|
Amount of Pain Medication - Day 1 to 7 Days
Time Frame: Assessed once during the 7 day follow-up
|
Total amount of pain medication used between day 1 and the 7 day follow-up call.
|
Assessed once during the 7 day follow-up
|
Amount of Pain Medication - 48 Hours to 7 Days
Time Frame: Assessed at the 48 hour follow-up and at the 7 day follow-up
|
Amount of pain medication the subject needed to use between the 48 hour follow-up and the 7 day follow-up.
|
Assessed at the 48 hour follow-up and at the 7 day follow-up
|
Number of Participants Requiring Additional Medical Assistance Post-Randomization
Time Frame: Assessed continuously from day 1 to the day 7 follow-up call
|
Need for additional medical intervention to treat the current episode of cellulitis.
|
Assessed continuously from day 1 to the day 7 follow-up call
|
Disposition Trend
Time Frame: Assessed once during day 1
|
Disposition of the subject at the end of the initial visit on day 1; "Disposition Trend" refers to whether the subject was discharged to home or admitted to observation unit in the hospital.
This Outcome Measure intends to assess improvement from baseline following intervention.
|
Assessed once during day 1
|
Adverse Events (AE)
Time Frame: Assessed continuously from day 1 to day 7 follow-up
|
Development of adverse events during study period such as: allergic reaction, development of severe sepsis or septic shock, crepitus, change in mentation, fever greater than or equal to 39 degrees Celsius, tachycardia (heart rate over 120 beats per minute)
|
Assessed continuously from day 1 to day 7 follow-up
|
Change in Erythema Size - Day 1 to 48 Hours
Time Frame: Calculated once at 48 hrs
|
Change in erythema size - day 1 to 48 hours = (Mean erythema at Day 1) - (Mean erythema at 48 hrs) Erythema is measured in millimeters using the most proximal and distal area of the erythema.
Higher values represent worse outcome.
|
Calculated once at 48 hrs
|
Collaborators and Investigators
Investigators
- Principal Investigator: Scott Goldstein, DO, Albert Einstein Healthcare Network
Publications and helpful links
General Publications
- Bergkvist PI, Sjobeck K. Antibiotic and prednisolone therapy of erysipelas: a randomized, double blind, placebo-controlled study. Scand J Infect Dis. 1997;29(4):377-82. doi: 10.3109/00365549709011834.
- Todd KH, Funk KG, Funk JP, Bonacci R. Clinical significance of reported changes in pain severity. Ann Emerg Med. 1996 Apr;27(4):485-9. doi: 10.1016/s0196-0644(96)70238-x.
- Kiderman A, Yaphe J, Bregman J, Zemel T, Furst AL. Adjuvant prednisone therapy in pharyngitis: a randomised controlled trial from general practice. Br J Gen Pract. 2005 Mar;55(512):218-21.
- Qi D, Pulinilkunnil T, An D, Ghosh S, Abrahani A, Pospisilik JA, Brownsey R, Wambolt R, Allard M, Rodrigues B. Single-dose dexamethasone induces whole-body insulin resistance and alters both cardiac fatty acid and carbohydrate metabolism. Diabetes. 2004 Jul;53(7):1790-7. doi: 10.2337/diabetes.53.7.1790.
- Yen MT, Yen KG. Effect of corticosteroids in the acute management of pediatric orbital cellulitis with subperiosteal abscess. Ophthalmic Plast Reconstr Surg. 2005 Sep;21(5):363-6; discussion 366-7. doi: 10.1097/01.iop.0000179973.44003.f7.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Infections
- Inflammation
- Connective Tissue Diseases
- Skin Diseases, Infectious
- Suppuration
- Cellulitis
- Physiological Effects of Drugs
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Prednisone
Other Study ID Numbers
- HN 4372
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cellulitis
-
McGill University Health Centre/Research Institute...CompletedCellulitis | Cellulitis of Leg | Cellulitis of ArmCanada
-
University of SouthamptonUniversity of Nottingham; Norfolk and Norwich University Hospitals NHS Foundation... and other collaboratorsNot yet recruitingCellulitis of Leg
-
Hillel Yaffe Medical CenterUnknown
-
University of SussexCompletedCellulitis | Cellulitis of Leg | Antibiotic DurationUnited Kingdom
-
University Hospital Plymouth NHS TrustTerminated
-
Lawson Health Research InstituteUniversity of Western Ontario, CanadaCompletedUncomplicated Outpatient CellulitisCanada
-
InMode MD Ltd.RecruitingCellulitis of LegUnited States
-
BTL Industries Ltd.CompletedCellulitis | Cellulite | Cellulitis of LegUnited States
-
Cairo UniversityRecruitingFibrosis | Lower Limb Lymphedema | Cellulitis of LegEgypt
-
Indústria Brasileira Equipamentos Médicos - IBRAMEDUnknown
Clinical Trials on Prednisone
-
Merck KGaA, Darmstadt, GermanyCompleted
-
University of South FloridaNational Heart, Lung, and Blood Institute (NHLBI); National Institute of Arthritis... and other collaboratorsActive, not recruitingVasculitis | Granulomatosis With Polyangiitis | Wegener GranulomatosisUnited States
-
Rabin Medical CenterUnknown
-
University of Alabama at BirminghamNational Institute of Neurological Disorders and Stroke (NINDS)CompletedMyasthenia GravisThailand, Canada, Germany, Italy, Netherlands, Brazil, United States, Argentina, Australia, Chile, Japan, Mexico, Poland, Portugal, South Africa, Spain, Taiwan, United Kingdom
-
University of PennsylvaniaNational Heart, Lung, and Blood Institute (NHLBI); National Institute of Arthritis... and other collaboratorsActive, not recruitingGranulomatosis With PolyangiitisUnited States, Canada
-
Federal University of São PauloFundação de Amparo à Pesquisa do Estado de São PauloUnknown
-
Fundación Pública Andaluza para la Investigación...Sociedad Andaluza de Trasplantes de Organos y TejidosCompletedRenal Transplant Rejection | Other Complication of Kidney TransplantSpain
-
Prof. Tony hayek MDCompletedDiabetes | Atherosclerosis | DyslipidemiasIsrael
-
Health Science Center of Xi'an Jiaotong UniversityUnknownFocal Segmental GlomerulosclerosisChina
-
National Institute for Tuberculosis and Lung Diseases...SuspendedInterstitial Lung Disease | Lung Neoplasm MalignantPoland